A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE007 (JPN) · Dr. Dubois
consented 2023-05-13
Adverse events
Grade 1 Asthenia — outcome: RECOVERED/RESOLVED; onset 2023-06-11 (study day 11); relationship: not assessed
Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-06-20 (study day 20); relationship: Y
Grade 3 Constipation — outcome: RECOVERED/RESOLVED; onset 2023-06-29 (study day 29); relationship: not assessed
Grade 2 Stomatitis — outcome: RECOVERED/RESOLVED; onset 2023-07-07 (study day 37); relationship: not assessed
Grade 4 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-09-06 (study day 98); relationship: not assessed; serious criteria: life-threatening
Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-09-12 (study day 104); relationship: not assessed
Grade 2 Anaemia — outcome: RECOVERED/RESOLVED; onset 2023-10-07 (study day 129); relationship: not assessed
Grade 3 Asthenia — outcome: RECOVERED/RESOLVED; onset 2023-10-17 (study day 139); relationship: Y; serious criteria: hospitalization
Data queries
No data queries.